Tecvayli Europäische Union - Deutsch - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - multiples myelom - antineoplastische mittel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Tecvayli 30 mg/3 ml Injektionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

tecvayli 30 mg/3 ml injektionslösung

janssen-cilag ag - teclistamabum - injektionslösung - teclistamabum 30 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 3 ml corresp. natrium 0.75 mg. - multiples myelom - biotechnologika

Tecvayli 153 mg/1.7 ml Injektionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

tecvayli 153 mg/1.7 ml injektionslösung

janssen-cilag ag - teclistamabum - injektionslösung - teclistamabum 153 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.7 ml corresp. natrium 0.43 mg. - multiples myelom - biotechnologika

Blenrep Europäische Union - Deutsch - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - multiples myelom - antineoplastische mittel - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Blenrep 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

blenrep 100 mg pulver für ein konzentrat zur herstellung einer infusionslösung

glaxosmithkline ag - belantamabum mafodotinum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: belantamabum mafodotinum 100 mg, natrii citras dihydricus, acidum citricum, trehalosum dihydricum, dinatrii edetas, polysorbatum 80, pro vitro corresp. natrium 3.15 mg. - multiples myelom - biotechnologika